EU Approves Troubled Abbott-Alere Deal – But Abbott Still Wants Out
The European Commission has approved Abbott Laboratories' pending acquisition of Alere, on condition that Alere's Epoc, Triage and BNP businesses are divested to alleviate anti-trust concerns. However, Abbott is still looking to cut loose from the $5.8bn deal.
You may also be interested in...
Alere is selling its Epocal point-of-care blood diagnostics subsidiary to Siemens Healthineers to comply with US antitrust requirements in advance of its pending acquisition by Abbott. Siemens plans to integrate Epocal's epoc blood analysis system with its digital platforms and its existing point-of-care diagnostics.
The global market for osteoporosis diagnostic products is expected to expand from $253m in 2015 to $304m by 2020, fueled by a rising aging population and the need to test for osteoporosis and associated fracture risk. This article offers an in-depth look at the growth markets for both bone densitometer testing and biochemical marker tests, as well as the evolving competitive landscape, and the drivers and barriers to market entry.
2017 kicked off with 12 medtech M&A acquisitions in January, a decline from the 18 M&A deals recorded in the same month last year, and two fewer than the previous month.